LAB vs SOFI · rev $174.4M vs P/E 39, rev $619.4M
Standard Biotools Inc (LAB) versus SoFi Technologies Inc. (SOFI) — a side-by-side from cached financials, not a winner call.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
SoFi Technologies Inc. (SOFI) is a credit services company listed on NASDAQ.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
Latest reported SOFI revenue for 2025-12-31 was $619.4M. Net income was $481.3M. Revenue was up 23.1% from 2024-12-31 to 2025-12-31. SOFI currently screens at market cap $22.25B and trailing P/E 38.5.
LAB currently screens at market cap $317.1M. SOFI currently screens at market cap $22.25B and trailing P/E 38.5.
Not investment advice. Open the LAB and SOFI stock pages for the full models.
Not investment advice.